Presentations & Publications

Presentation

Advaxis’ Listeria monocytogenes-based immunotherapies rapidly impair intratumoral regulatory T cell survival and function and promote effector T cell recruitment, activation and differentiation

SITC, November 13, 2017

Presentation

Molecular signatures of combination immunotherapy of prostate cancer using a Listeria-based PSA vaccine and radiation

SITC, November 13, 2017

Presentation

Combination immunotherapy of murine prostate cancer using a Listeria-based PSA vaccine: immune correlates of efficacy and resistance development

SITC, November 13, 2017

Presentation

ADXS-PSA immunotherapy increases the magnitude and quality of prostate cancer-antigenspecific T cell responses in patients with metastatic castration-resistant prostate cancer

SITC, November 13, 2017

Presentation

Baseline serum protein levels associated with survival in axalimogene filolisbac (AXAL)-treated metastatic cervical cancer patients: The GOG/NRG-0265 trial

ESGO, November 2017

Presentation

Identification of an intratumoral immune gene signature associated with tumor regression in an axalimogene filolisbac-treated murine HPV+ tumor model

CRI-CIMT-EATI-AACR, September 9, 2017

Presentation

Persistence of expanded TCRß clonotypes is associated with clinical activity of ADXS-PSA immunotherapy in metastatic castration-resistant prostate cancer

CRI-CIMT-EATI-AACR, September 9, 2017

Presentation

Gene expression profiles associated with stable disease in metastatic castration resistant prostate cancer patients treated with ADXS-PSA immunotherapy

CRI-CIMT-EATI-AACR, September 9, 2017

Publication

Therapeutic options for treatment of human papillomavirus-associated cancers – novel immunologic vaccines: ADXS11–001

Published in Gynecologic Oncology Research and Practice on July 14, 2017

Publication

Blood Protein Levels May Predict Cervical Cancer Patients Likely to Benefit from Advaxis’ Immunotherapy

Published in Immuno-Oncology News, June 29, 2017

Presentation

2017 Investor Analyst Day

June 12, 2017

Publication

Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy

Published in Gynecologic Oncology Research and Practice on June 2, 2017

Presentation

HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity (#7632)

AACR, September 2016

Presentation

ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage 1 [and stage 2] of the phase II GOG/NRG-0265 study

ASCO, June 6, 2016

Presentation

ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage 1 [and stage 2] of the phase II GOG/NRG-0265 study

ASCO, June 6, 2016